Pharmaceutical company Crossject (Euronext Growth Paris:ALCJ) announced on Wednesday that it has received EUR6.9m in public funding from the French government's France 2030 plan to accelerate the development of its ZENEO Epinephrine auto-injector.
The funding, primarily grants with some subsidised loans, supports Crossject's innovative project to create a needle-free emergency treatment for severe allergic reactions.
ZENEO Epinephrine boasts a patented, sulphite-free formulation designed for reduced allergy risks and longer shelf life. The auto-injector ensures complete and rapid medication delivery.
Crossject aims to file for regulatory approval in Europe and the United States by 2026.
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices